EP4719366A1 - Sortilin-hemmer zur behandlung von patienten mit funktionellen neuroendokrinen tumoren - Google Patents

Sortilin-hemmer zur behandlung von patienten mit funktionellen neuroendokrinen tumoren

Info

Publication number
EP4719366A1
EP4719366A1 EP24725852.8A EP24725852A EP4719366A1 EP 4719366 A1 EP4719366 A1 EP 4719366A1 EP 24725852 A EP24725852 A EP 24725852A EP 4719366 A1 EP4719366 A1 EP 4719366A1
Authority
EP
European Patent Office
Prior art keywords
sortilin
inhibitor
carbamoyl
benzoic acid
methylpyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24725852.8A
Other languages
English (en)
French (fr)
Inventor
Michael SIGAL
Felix BOLDUAN
Bertram Wiedenmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP4719366A1 publication Critical patent/EP4719366A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24725852.8A 2023-05-26 2024-05-10 Sortilin-hemmer zur behandlung von patienten mit funktionellen neuroendokrinen tumoren Pending EP4719366A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23175836 2023-05-26
PCT/EP2024/062984 WO2024245719A1 (en) 2023-05-26 2024-05-10 Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors

Publications (1)

Publication Number Publication Date
EP4719366A1 true EP4719366A1 (de) 2026-04-08

Family

ID=86605642

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24725852.8A Pending EP4719366A1 (de) 2023-05-26 2024-05-10 Sortilin-hemmer zur behandlung von patienten mit funktionellen neuroendokrinen tumoren

Country Status (2)

Country Link
EP (1) EP4719366A1 (de)
WO (1) WO2024245719A1 (de)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132656A2 (en) 2008-04-27 2009-11-05 H. Lundbeck A/S Design of specific ligands to sortilin
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
US10180422B1 (en) * 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
EP3881840A1 (de) 2020-03-19 2021-09-22 Insusense ApS Sortilin antagonisten in der verwendung zur behandlung von diabetischer retinopathie
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
EP4032891A1 (de) 2021-01-20 2022-07-27 Insusense ApS Pyridin-derivate als modulatoren der sortilin-aktivität
EP4079748A1 (de) 2021-04-23 2022-10-26 Insusense ApS Modulatoren von sortilinaktivität
EP4089102A1 (de) 2021-05-14 2022-11-16 Insusense ApS Modulatoren von sortilinaktivität
EP4144352A1 (de) 2021-09-03 2023-03-08 Insusense ApS 2-amino-5,5-dimethylhexansäure-derivate als sortilin-modulatoren zur behandlung von erkrankungen des zentralen nervensystems
SE545408C2 (en) 2021-12-02 2023-09-05 Sortina Pharma Ab Sortilin inhibitors
EP4234014A1 (de) 2022-02-28 2023-08-30 Insusense ApS Von aminosäuren abgeleitete carbamate und/oder harnstoffe zur behandlung sortilin-abhängiger krankheiten
EP4342530A1 (de) 2022-09-02 2024-03-27 Insusense ApS Sortilin modulatoren

Also Published As

Publication number Publication date
WO2024245719A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
Fu et al. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics
JP7536049B2 (ja) 血管新生障害の処置
CN114144423A (zh) 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症
EP4025590A1 (de) Verfahren und zusammensetzungen zur behandlung von krebs
Umbarkar et al. Repurposing Nintedanib for pathological cardiac remodeling and dysfunction
JP2025011102A (ja) 肝疾患を治療するための組成物および方法
JP2021527651A (ja) Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法
WO2012064967A2 (en) Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
US20130263297A1 (en) Methods of treating cancer
WO2024245719A1 (en) Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
CN112353940B (zh) 一种用于预防或治疗抑郁症的药物及其应用
JP2026506642A (ja) 神経膠腫を治療する方法
WO2021075559A1 (ja) 癌関連線維芽細胞の細胞増殖阻害剤又は細胞死誘導剤
US20210024937A1 (en) Methods of Modulating Lymphangiogenesis, E.g., to Treat Corneal Transplant Rejection, in a Subject
US20220193113A1 (en) Novel therapeutic agent for gastrointestinal cancer and method for screening for the same
JP2025521567A (ja) 胆汁うっ滞及び／又は胆汁うっ滞に関連する線維症の予防、進行の遅延又は治療のための方法
WO2024204685A1 (ja) 癌の治療および／または予防のための医薬組成物
CN116173040A (zh) Xmd17109作为arih1激动剂的用途
JP2014105177A (ja) 糖尿病治療用医薬組成物及びその有効成分のスクリーニング方法
HK40023089A (en) Method for identifying nucleic acids regulating metastasation
HK1245330B (en) Method for identifying nucleic acids regulating metastasation
HK1193429A (en) Treatment of angiogenesis disorders
HK1193429B (en) Treatment of angiogenesis disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR